Genomic Cancer Testing Market Size, Share & Trends Analysis Report By Test Type (Genomic Profiling Tests, Liquid Biopsy Tests, Companion Diagnostic Tests, Pharmacogenomic Tests, Hereditary Cancer Tests, Other specialized genomic tests), By Cancer Type, By Technology, By End-User, By Biomarker Type, By Service Provider, By Application, By Testing Setting, By Region, And By Segment Forecasts, 2025-2034

Report Id: 2267 Pages: 179 Last Updated: 10 June 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Genomic Cancer Testing Market-

Genomic Cancer Testing Market By Test Type-

  • Genomic Profiling Tests
  • Liquid Biopsy Tests
  • Companion Diagnostic Tests
  • Pharmacogenomic Tests
  • Hereditary Cancer Tests
  • Other specialized genomic tests

genomic cancer testing

Genomic Cancer Testing Market By Cancer Type-

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Melanoma
  • Leukaemia
  • Lymphoma
  • Other specific cancer types

Genomic Cancer Testing Market By Technology-

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In Situ Hybridization (FISH)
  • Microarray
  • Immunohistochemistry (IHC)
  • Other genomic testing technologies

Genomic Cancer Testing Market By End-User-

  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Cancer Centers
  • Other healthcare providers

Genomic Cancer Testing Market By Biomarker Type-

  • Genetic Biomarkers
  • Protein Biomarkers
  • Molecular Biomarkers
  • Epigenetic Biomarkers

Genomic Cancer Testing Market By Service Provider-

  • Diagnostic Laboratories
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Contract Research Organizations (CROs)

Genomic Cancer Testing Market By Application-

  • Targeted Therapy Selection
  • Disease Monitoring
  • Prognostic Testing
  • Companion Diagnostics
  • Risk Assessment
  • Pharmacogenomic Testing

Genomic Cancer Testing Market By Testing Setting-

  • In-House Testing
  • Outsourced Testing

Genomic Cancer Testing Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Genomic Cancer Testing Market Snapshot

Chapter 4. Global Genomic Cancer Testing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis

5.1. By Technology, & Market Share, 2024 & 2034

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology:

5.2.1. Next-Generation Sequencing (NGS)

5.2.2. Polymerase Chain Reaction (PCR)

5.2.3. Fluorescence In Situ Hybridization (FISH)

5.2.4. Microarray

5.2.5. Immunohistochemistry (IHC)

5.2.6. Other genomic testing technologies

Chapter 6. Market Segmentation 2: By Test Type Estimates & Trend Analysis

6.1. By Test Type & Market Share, 2024 & 2034

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Test Type:

6.2.1. Genomic Profiling Tests

6.2.2. Liquid Biopsy Tests

6.2.3. Companion Diagnostic Tests

6.2.4. Pharmacogenomic Tests

6.2.5. Hereditary Cancer Tests

6.2.6. Other specialized genomic tests

Chapter 7. Market Segmentation 3: By Cancer Type Estimates & Trend Analysis

7.1. By Cancer Type & Market Share, 2024 & 2034

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Cancer Type:

7.2.1. Breast Cancer

7.2.2. Lung Cancer

7.2.3. Colorectal Cancer

7.2.4. Prostate Cancer

7.2.5. Ovarian Cancer

7.2.6. Melanoma

7.2.7. Leukemia

7.2.8. Lymphoma

7.2.9. Other specific cancer types

Chapter 8. Market Segmentation 4: By End-User Estimates & Trend Analysis

8.1. By End-User & Market Share, 2024 & 2034

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-User:

8.2.1. Hospitals

8.2.2. Diagnostic Laboratories

8.2.3. Academic and Research Institutions

8.2.4. Cancer Centers

8.2.5. Other healthcare providers

Chapter 9. Market Segmentation 5: By Biomarker Type Estimates & Trend Analysis

9.1. By Biomarker Type & Market Share, 2024 & 2034

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Biomarker Type:

9.2.1. Genetic Biomarkers

9.2.2. Protein Biomarkers

9.2.3. Molecular Biomarkers

9.2.4. Epigenetic Biomarkers

Chapter 10. Market Segmentation 6: By Service Provider Estimates & Trend Analysis

10.1. By Service Provider & Market Share, 2024 & 2034

10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Service Provider:

10.2.1. Diagnostic Laboratories

10.2.2. Biotechnology Companies

10.2.3. Pharmaceutical Companies

10.2.4. Contract Research Organizations (CROs)

Chapter 11. Market Segmentation 7: By Application Estimates & Trend Analysis

11.1. By Application & Market Share, 2024 & 2034

11.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:

11.2.1. Targeted Therapy Selection

11.2.2. Disease Monitoring

11.2.3. Prognostic Testing

11.2.4. Companion Diagnostics

11.2.5. Risk Assessment

11.2.6. Pharmacogenomic Testing

Chapter 12. Market Segmentation 8: By Testing Setting Estimates & Trend Analysis

12.1. By Testing Setting & Market Share, 2024 & 2034

12.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Testing Setting:

12.2.1. In-House Testing

12.2.2. Outsourced Testing

Chapter 13. Genomic Cancer Testing Market Segmentation 9: Regional Estimates & Trend Analysis

13.1. North America

13.1.1. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Technology, 2021-2034

13.1.2. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Test Type, 2021-2034

13.1.3. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Cancer Type, 2021-2034

13.1.4. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By End-User, 2021-2034

13.1.5. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Biomarker Type, 2021-2034

13.1.6. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Service Provider, 2021-2034

13.1.7. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Application, 2021-2034

13.1.8. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts By Testing Setting, 2021-2034

13.1.9. North America Genomic Cancer Testing Market revenue in US$ Million estimates and forecasts by country, 2021-2034

13.2. Europe

13.2.1. Europe Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034

13.2.2. Europe Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034

13.2.3. Europe Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034

13.2.4. Europe Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034

13.2.5. Europe Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034

13.2.6. Europe Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034

13.2.7. Europe Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034

13.2.8. Europe Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034

13.2.9. Europe Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034

13.3. Asia Pacific

13.3.1. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Technology, 2021-2034

13.3.2. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Test Type, 2021-2034

13.3.3. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, 2021-2034

13.3.4. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By End-User, 2021-2034

13.3.5. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, 2021-2034

13.3.6. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Service Provider, 2021-2034

13.3.7. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Application, 2021-2034

13.3.8. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, 2021-2034

13.3.9. Asia Pacific Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034

13.4. Latin America

13.4.1. Latin America Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034

13.4.2. Latin America Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034

13.4.3. Latin America Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034

13.4.4. Latin America Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034

13.4.5. Latin America Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034

13.4.6. Latin America Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034

13.4.7. Latin America Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034

13.4.8. Latin America Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034

13.4.9. Latin America Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034

13.5. Middle East & Africa

13.5.1. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Technology, (US$ Million) 2021-2034

13.5.2. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Test Type, (US$ Million) 2021-2034

13.5.3. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Cancer Type, (US$ Million) 2021-2034

13.5.4. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By End-User, (US$ Million) 2021-2034

13.5.5. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Biomarker Type, (US$ Million) 2021-2034

13.5.6. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Service Provider, (US$ Million) 2021-2034

13.5.7. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Application, (US$ Million) 2021-2034

13.5.8. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million By Testing Setting, (US$ Million) 2021-2034

13.5.9. Middle East & Africa Genomic Cancer Testing Market revenue in US$ Million by country, 2021-2034

Chapter 14. Competitive Landscape

14.1. Major Mergers and Acquisitions/Strategic Alliances

14.2. Company Profiles

14.2.1. Illumina, Inc.,

14.2.2. Thermo Fisher Scientific, Inc.,

14.2.3. Qiagen N.V.,

14.2.4. F. Hoffmann-La Roche Ltd.,

14.2.5. Foundation Medicine, Inc. (Roche),

14.2.6. Invitae Corporation,

14.2.7. NeoGenomics Laboratories, Inc.,

14.2.8. Myriad Genetics, Inc.,

14.2.9. Genomic Health, Inc. (Exact Sciences Corporation),

14.2.10. Caris Life Sciences,

14.2.11. ArcherDX, Inc. (Invitae Corporation),

14.2.12. Guardant Health, Inc.,

14.2.13. Personal Genome Diagnostics Inc.,

14.2.14. Biocept, Inc.,

14.2.15. Tempus Labs, Inc.

14.2.16. Danaher

14.2.17. PerkinElmer

14.2.18. Agilent Technologies, Inc

14.2.19. Quest Diagnostics

14.2.20. Luminex Corporation

14.2.21. Others

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
3780
Security Code field cannot be blank!

Frequently Asked Questions

Genomic Cancer Testing Market Size is valued at USD 18.47 billion in 2024 and is predicted to reach USD 86.13 billion by the year 2034

Genomic Cancer Testing Market expected to grow at a 16.8% CAGR during the forecast period for 2025-2034.

Biocept, Inc., and Tempus Labs, Inc., Danaher, PerkinElmer, Agilent Technologies, Inc., Quest Diagnostics, Luminex Corporation

Genomic Cancer Testing Market is segmented based on test type, cancer type, technology, end-user, biomarker type, service provider, application, and t

North America region is leading the Genomic Cancer Testing Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying